Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Advances in™ Biomarkers: How Can I Utilize Tumor Mutational Burden in My Practice?

Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

This activity, Advances in™ Biomarkers: How Can I Utilize Tumor Mutational Burden in My Practice?, developed in Physicians’ Education Resource®, LLC, (PER®) established Advances in™ legacy format, will highlight the evolving biomarker landscape to predict response to checkpoint inhibitors, including PD-L1, microsatellite instability, tumor mutational burden, and other biomarkers on the horizon. The role of next-generation sequencing to assess biomarkers in clinical practice will also be reviewed.

You will hear experts discuss data supporting established and investigational biomarkers, as they provide their perspectives on how the evolving biomarker landscape may impact the future, and guide participants on its potential application to clinical practice.

Benefits of Completing Activity

By participating in this exciting program, you will learn about:

  • Biomarkers being used in current clinical practice to guide cancer immunotherapy treatment with checkpoint inhibitors
  • The evidence for using tumor mutational burden to guide checkpoint inhibitor treatment decisions
  • The evolving role of next-generation sequencing in optimizing care of patients with cancer

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, pathologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Describe the various mechanisms by which the immune system can be targeted in the treatment of various tumor types.
  2. Discuss the prevalence of current biomarkers in tumor types and their clinical use.
  3. Identify the potential for TMB as a biomarker in selecting immunotherapy for individual patients.
  4. Recognize the role of NGS to identify tumor mutation load, including TMB, MI, and dMMR in a single assay that includes traditional targetable mutations.

Faculty, Staff, and Planners' Disclosures


Hossein Borghaei
Hossein Borghaei, MS, DO
Chief, Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant/Research Support: Millennium, Merck/Celgene, BMS/Lilly; Consultant: BMS, Lilly, Genentech, Celgene, Pfizer, Merck, EMD Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, AbbVie, Axiom

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center, Smilow Cancer Hospital
New Haven, CT

Disclosures: Consultant: AbbVie Pharmaceuticals, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech/Roche, Heat Biologics, Jun Shi Pharmaceuticals, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, TESARO; Research Support: AstraZeneca, Eli Lilly and Company, Merck and Company; Scientific Advisory Boards: Neon Therapeutics, Infinity Pharmaceuticals, NextCure

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By